Omnicell, Inc. (NASDAQ:OMCL) Short Interest Update

Omnicell, Inc. (NASDAQ:OMCL) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 2,120,000 shares, a growth of 55.9% from the November 15th total of 1,360,000 shares. Based on an average trading volume of 572,300 shares, the short-interest ratio is presently 3.7 days.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Omnicell

Several institutional investors have recently modified their holdings of OMCL. Victory Capital Management Inc. grew its position in shares of Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after buying an additional 1,138,921 shares during the period. Federated Hermes Inc. grew its holdings in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the period. Sumitomo Mitsui Trust Group Inc. acquired a new position in Omnicell during the third quarter valued at approximately $32,721,000. Pacer Advisors Inc. grew its holdings in Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Omnicell by 750.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Up 0.1 %

Shares of NASDAQ:OMCL traded up $0.05 during trading on Friday, hitting $46.01. 296,981 shares of the company’s stock were exchanged, compared to its average volume of 535,995. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The firm has a 50-day moving average price of $45.25 and a two-hundred day moving average price of $38.90. The firm has a market cap of $2.13 billion, a P/E ratio of -117.46, a PEG ratio of 35.72 and a beta of 0.77.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Benchmark restated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Finally, Barclays raised their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average target price of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.